|Bid||521.50 x 200|
|Ask||525.00 x 100|
|Day's range||510.70 - 521.77|
|52-week range||325.35 - 543.55|
|PE ratio (TTM)||63.09|
|Earnings date||3 Aug 2017|
|Dividend & yield||N/A (N/A)|
|1y target est||479.00|
MAIN, GERMANY / ACCESSWIRE / July 24, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ), following which ...
Sanofi and Regeneron Receive Positive CHMP Opinion for Dupixent ® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis - First investigational targeted biologic in the European ...
The European Medicines Agency on Friday recommended approval of Regeneron Pharmaceuticals and Sanofi's new drug Dupixent for atopic dermatitis, a product many analysts see as the most important growth driver for the two companies. Recommendations from the agency's expert committee on new drugs are normally endorsed by the European Commission within a couple of months. Atopic dermatitis is a chronic type of skin inflammation also known as eczema, which in severe cases causes constant, often unbearable, itching.